Global High-flow Nasal Cannula Market Size

High Flow Nasal Cannula Market Analysis

The global high-flow nasal cannula market is projected to witness a CAGR of nearly 12.4% over the forecast period (2022 - 2027).

The COVID-19 pandemic has significantly impacted the high-flow nasal cannula market. Several studies were carried out indicating the use of high-flow nasal cannula for COVID-19 patients. For instance, according to an article published by Multidisciplinary Respiratory Medicine, in September 2020, titled " High-flow nasal cannula for Acute Respiratory Distress Syndrome (ARDS) due to COVID-19", a retrospective, observational study was performed at a single center, evaluating patients with ARDS secondary to COVID-19 treated with a high-flow nasal cannula. In addition, high-flow therapy is found to be an effective treatment for ARDS that can be used to delay intubation or as a bridge therapy. Also, no higher mortality was seen as a result of this delay. Similarly, as per an article published by JAMA Network Journal, in December 2021, titled "Effect of High-Flow Oxygen Therapy vs Conventional Therapy on Invasive Mechanical Ventilation and Clinical Recovery in Patients with Severe COVID-19", it has been observed that high-flow oxygen therapy reduced the need for invasive mechanical ventilation and ramped up clinical recovery in patients with severe COVID-19 as compared to conventional oxygen therapy. Thus, the increased usage and clinical recovery of patients with high-flow oxygen therapy with nasal cannula during the pandemic are expected to increase the demand for the high-flow nasal cannula, thereby boosting the market growth.

The major factors contributing to the market growth are the rising incidences of respiratory disorders and increasing technological advancements in the high-flow nasal cannula systems.

The rising incidences of respiratory disorders are the key factor driving the market growth. For instance, according to the 2022 statistics published by the Australian Bureau of Statistics, 10.7% of the total population has asthma in 2020-2021. In addition, as per the same source, the highest prevalence of asthma was found in females (12%) as compared to males (9.4%). Moreover, according to the same source, the rate of asthma in boys and girls aged 0-14 years was 9.5% and 7.9%, respectively. Also, according to a December 2021 published article titled, high-flow nasal cannula in children with asthma exacerbation: A review of current evidence, high-flow oxygen therapy administered through a nasal cannula (HFNC) provides respiratory support with adequate airway humidity and has demonstrated safety and benefits in clinical practice. Thus, the growing burden of asthma is contributing to the increasing demand for high-flow nasal cannulas. Thus, the rising burden of respiratory diseases among the population is expected to rise the demand for high-flow oxygen therapy through a nasal cannula, which is expected to rise the market growth over the forecast period.

However, the limitations associated with high-flow nasal cannula are a major factor restraining the market growth.